Pritish Iyer
YOU?
Author Swipe
View article: LBODP064 A Rare Case Of Paraneoplastic Cushing Syndrome Associated With Pulmonary Carcinoid Tumor
LBODP064 A Rare Case Of Paraneoplastic Cushing Syndrome Associated With Pulmonary Carcinoid Tumor Open
A 67-year-old female with a history of primary pulmonary carcinoid tumor with metastasis to the liver presented with shortness of breath and generalized weakness. On presentation, her vital signs were BP 170/100 mm Hg, pulse 99/min, RR 18/…
View article: Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine Open
Background: Most safety and efficacy trials of the SARS-CoV-2 vaccines excluded patients with cancer, yet these patients are more likely than healthy individuals to contract SARS-CoV-2 and more likely to become seriously ill after infectio…
View article: Diffuse gastric cancer: histologic, molecular, and genetic basis of disease
Diffuse gastric cancer: histologic, molecular, and genetic basis of disease Open
Diffuse gastric cancer (DGC) is a distinct histopathologic and molecular disease, characterized by mutations in CDH1, RHOA, and others. In addition, DGC is associated with familial syndromes, including hereditary DGC and germline mutation …
View article: Targets for therapy in biliary tract cancers: the new horizon of personalized medicine
Targets for therapy in biliary tract cancers: the new horizon of personalized medicine Open
Biliary tract cancers (BTCs) are a set of molecularly distinct and heterogeneous diseases. While cytotoxic chemotherapy remains the current standard of care for treatment-naïve and treatment-refractory unresectable disease, recently identi…
View article: Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)
Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC) Open
Background: HA in the tumor microenvironment can inhibit the effectiveness of anticancer agents. The novel biologic PEGPH20 degrades pathological HA accumulation. EM is a microtubule inhibitor approved for the treatment of pts with MBC who…